Adjuvant 5-FU and LMV Heparin fails to prevent Proliferative vitreoretinopathy after primary RRD
A recent trial found that the incidence of Proliferative vitreoretinopathy (PVR) in high-risk patients with primary rhegmatogenous retinal detachment did not improve by adding adjuvant therapy with 5-FU and Low molecular weight heparin. The trial results were published in the journal Ophthalmology.
Proliferative vitreoretinopathy (PVR) is an anomalous scarring process and is the major cause of postoperative failure and retinal redetachment after primary rhegmatogenous retinal detachment (RRD). There is no standard therapy to prevent or treat PVR. Previous studies have shown good results for 5-fluorouracil (5-FU) and low-molecular-weight heparin (LMWH) in high-risk eyes. Hence researchers conducted a trial called the PRIVENT trial to examine the effect of adjuvant intravitreal therapy with 5-FU and LMWH compared with placebo on the incidence of PVR in high-risk patients with primary RRD.
A randomized, double-blind, controlled, multicenter, interventional trial with 1 interim analysis was conducted at thirteen German trial sites involving five hundred sixty patients. Patients with RRD at high risk for PVR were included. Noninvasive aqueous flare measurement using laser flare photometry was used to assess the risk of PVR. Patients were randomized 1:1 to verum with 200 mg/ml 5-FU and 5 IU/ml dalteparin and placebo which is a balanced salt solution intravitreally applied during routine pars plana vitrectomy. The primary endpoint was the development of PVR grade CP which is full-thickness retinal folds or subretinal strands in clock hours located posterior to equator 1 or higher within 12 weeks after surgery. An endpoint committee graded based on the fundus photographs. Secondary endpoints included best-corrected visual acuity and redetachment rate. A group sequential design with 1 interim analysis was applied using the O'Brien and Fleming boundaries. Proliferative vitreoretinopathy grade CP incidence was compared using a Mantel-Haenszel test stratified by the surgeon.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.